These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

5163 related articles for article (PubMed ID: 5514625)

  • 1. An evaluation of large intermittent intravenous doses of cyclophosphamide (NSC-26271) in the treatment of metastatic malignant melanoma.
    Gottlieb JA; Mendelson D; Serpick AA
    Cancer Chemother Rep; 1970 Oct; 54(5):365-7. PubMed ID: 5514625
    [No Abstract]   [Full Text] [Related]  

  • 2. Acceleration of bone-marrow recovery by pre-treatment with cyclophosphamide in patients receiving high-dose melphalan.
    Hedley DW; McElwain TJ; Millar JL; Gordon MY
    Lancet; 1978 Nov; 2(8097):966-8. PubMed ID: 81990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen in the treatment of metastatic malignant melanoma.
    Wagstaff J; Thatcher N; Rankin E; Crowther D
    Cancer Treat Rep; 1982 Sep; 66(9):1771. PubMed ID: 7116353
    [No Abstract]   [Full Text] [Related]  

  • 4. A comparative study of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037) and imidazole carboxamide (NSC 45388) with vincristine (NSC 67574) in the palliation of disseminated malignant melanoma.
    Ahmann DL; Hahn RG; Bisel HF
    Cancer Res; 1972 Nov; 32(11):2432-4. PubMed ID: 5082592
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of metastatic malignant melanoma with a combination of 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388), cyclophosphamide (NSC-26271), and vincristine (NSC-67574).
    Gardere S; Hussain S; Cowan DH
    Cancer Chemother Rep; 1972 Jun; 56(3):357-61. PubMed ID: 19051495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-schedule studies with hydroxyurea (NSC-32065) in malignant melanoma.
    Gottlieb JA; Frei E; Luce JK
    Cancer Chemother Rep; 1971 Jun; 55(3):277-80. PubMed ID: 5115848
    [No Abstract]   [Full Text] [Related]  

  • 7. [Problems in the radiological treatment of malignant melanomas of the skin. Report on 136 patients followed-up over long period of time].
    Koenig H
    Z Arztl Fortbild (Jena); 1970 Aug; 64(15):770-9. PubMed ID: 5523013
    [No Abstract]   [Full Text] [Related]  

  • 8. [Nitrosomethylurea in the treatment of patients with disseminated cutaneous melanoma].
    Dement'eva NP; Koroleva LA
    Vopr Onkol; 1984; 30(7):51-4. PubMed ID: 6464402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathomorphosis of metastatic malignant melanoma of the skin as effected by preoperative endolymphatic polychemotherapy].
    Naleskina LA; Tolstopiatov BA; Korovin SI
    Klin Khir (1962); 1993; (5):27-30. PubMed ID: 7933857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA approves new treatment of metastatic melanoma.
    Printz C
    Cancer; 2016 Apr; 122(8):1149. PubMed ID: 27061518
    [No Abstract]   [Full Text] [Related]  

  • 11. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial.
    Ellebaek E; Engell-Noerregaard L; Iversen TZ; Froesig TM; Munir S; Hadrup SR; Andersen MH; Svane IM
    Cancer Immunol Immunother; 2012 Oct; 61(10):1791-804. PubMed ID: 22426890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy of disseminated malignant melanoma with imidazol carboxamide (DTIC) and cyclophosphamide. Preliminary results.
    Rudolf Z; Plesnicar S
    Anticancer Res; 1982; 2(1-2):37-9. PubMed ID: 7051959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of intravenous phytohaemagglutinin in a patient with disseminated malignant melanoma: a clinical and immunological study.
    Lewis MG; Humble JG; Lee ES; Phillips TM
    Rev Eur Etud Clin Biol; 1971 Nov; 16(9):924-7. PubMed ID: 5168456
    [No Abstract]   [Full Text] [Related]  

  • 14. Intermittent high-dose cyclophosphamide (NSC-26271) treatment of stage III ovarian carcinoma.
    Buckner CD; Briggs R; Clift RA; Fefer A; Funk DD; Glucksberg H; Neiman PE; Storb R; Thomas ED
    Cancer Chemother Rep; 1974; 58(5 Pt 1):697-703. PubMed ID: 4426048
    [No Abstract]   [Full Text] [Related]  

  • 15. A clinicopathologic study of amelanotic melanoma.
    Huvos AG; Shah JP; Goldsmith HS
    Surg Gynecol Obstet; 1972 Dec; 135(6):917-20. PubMed ID: 5086000
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II study of tamoxifen in patients with metastatic malignant melanoma.
    Telhaug R; Klepp O; Børmer O
    Cancer Treat Rep; 1982 Jun; 66(6):1437. PubMed ID: 7083247
    [No Abstract]   [Full Text] [Related]  

  • 17. [Chemotherapy of generalized skin melanoma].
    Dement'eva NP; Koroleva LA
    Sov Med; 1981; (10):103-6. PubMed ID: 7313762
    [No Abstract]   [Full Text] [Related]  

  • 18. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
    Eisen T; Trefzer U; Hamilton A; Hersey P; Millward M; Knight RD; Jungnelius JU; Glaspy J
    Cancer; 2010 Jan; 116(1):146-54. PubMed ID: 19862820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives.
    Durando X; Thivat E; D'Incan M; Sinsard A; Madelmont JC; Chollet P
    BMC Cancer; 2005 Nov; 5():147. PubMed ID: 16287507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adriamycin (NSC-123127) in combination with cyclophosphamide (NSC-26271): a phase I and II evaluation.
    Muggia FM; Perloff M; Chia GA; Reed LJ; Escher GC
    Cancer Chemother Rep; 1974; 58(6):919-26. PubMed ID: 4614899
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 259.